BioClonetics is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies for use in the diagnosis and treatment of HIV/AIDS and other infectious diseases. BioClonetics has created a human cell line that produces a human antibody (designated as CLONE 3) that neutralizes HIV, the virus that causes AIDS.
Metabolic Pharmaceuticals Limited (Metabolic) is an Australia-based biotechnology company. The Company developed a drug development platform, oral versions of a variety of injected peptide drugs. Metabolic has been working in collaboration with Neuren Pharmaceuticals Limited (NZ) to develop Neural Regeneration Peptides (NRPs), a group of small peptide drugs that appear to protect nerves from damage and help them recover. In August 2007 Metabolic discontinued the development of ACV1 for the treatment of various neuropathic pain conditions. (Source: ARS)
InKine Pharmaceutical Company, Inc. is a publicly traded specialty pharmaceutical company focused on developing and commercializing pharmaceutical products for the diagnosis and treatment of gastrointestinal disorders. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's franchise product, Visicol® is the only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IB-Stat®, is an oral hyoscyamine spray for the treatment of a variety of indications. The Company is also promoting VSL#3®, a probiotic that is effective in treating certain gastrointestinal disorders. Additionally, the Company is developing INKP-102, an advanced generation purgative, which recently completed Phase II clinical trials for bowel cleansing prior to colonoscopy, Visicol® for use as a laxative in treating patients with constipation.
TopoTarget A/S is a Denmark-based biotech company. It is focused on treatments for cancer patients and other cancer-related disorders. Its activities cover various aspects of drug development, including assay development, screening, biology, medicinal chemistry, preclinical and clinical trials, regulatory affairs, business development and marketing and sales. TopoTarget’s main product is Savene/Totect. Its clinical pipeline has six drug candidates in Phase II: a clinical compound belinostat (PXD101), oncology products APO866, Siramesine, Baceca, Savicol and the non-oncology drug candidate Avugane. Additionally, it has three oncology products in Phase I development (Zemab, APO010 and Topotect). The Company also has a number of earlier stage cancer products in pre-clinical development, including HDAC inhibitors, as well as HSP90 and mTOR modulators. TopoTarget has operations in Denmark, the United States, Switzerland, the United Kingdom and Germany.
Forbes Medi-Tech Inc. (Forbes) is a life sciences company dedicated to the research, development and commercialization of products for the prevention and treatment of life-threatening diseases. The Company’ infrastructure supports a portfolio of discovery and development stage pharmaceutical compounds and nutraceutical products. Its pharmaceutical compounds are primarily targeting a number of conditions and diseases associated with metabolic syndrome, including cardiovascular disease and type 2 diabetes. The Company's nutraceutical products, both commercialized and under development, are intended to help reduce the risk of cardiovascular disease and the conditions that can cause it. On February 27, 2008, the Company acquired Forbes Medi-Tech Inc. (Old Forbes). As a result, Old Forbes became a wholly owned subsidiary of New Forbes, and changed its name to Forbes Medi-Tech Operations Inc. (Source: 20-F)
Axonyx Inc. is a U.S.-based biopharmaceutical company engaged in the acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's disease, human memory disorders and prion-based illnesses such as Mad Cow disease. Its leading Alzheimer's disease drug candidate is Phenserine, a dual action acetylcholinesterase and beta amyloid precursor protein ((B)-APP) inhibitor, and currently in Phase IIB and Phase III clinical trials. A previously completed Phase II trial showed that Phenserine was well tolerated and effective in improving the memory of mild-to-moderate AD patients. The ongoing Phase IIB clinical study is designed to evaluate Phenserine's ability to lower the levels of the beta-amyloid precursor protein ((B)-APP) and Amyloid beta (A-(B)) in the plasma and cerebrospinal fluid of mild-to-moderate AD patients. The presence of toxic beta-amyloid in the brains of AD patients is considered by many experts to be a key pathological event in the causation as well as the progression of AD. A reduction of these levels may be able to slow the progression of AD.
About GEN ... Freelance health care reporter business copywriter medical writer Words Come Alive provides the best in freelance reporting for health care and business. ... Source: MedZilla.com. Biotechnology recruiting is hot. It's more active than IT ... that targets jobseekers and HR Professionals in biotechnology, pharmaceuticals, healthcare and science ... RSI - Executive Search Recruiter | Biotechnology Recruiting, Biotechnology E ... Biotechnology Recruiter / Biotechnology Executive Search Medical Device Recruiter / Medical Device Executive Search Scientific Search Area RSI is synonymous with Biotechnology Recruiting ... Breaking News: Global Entrepreneurs Programme Hosts Biotechnology Recruiting ...
Alltracel (http://www.alltracel.com) Alltracel Pharmaceuticals PLC is an innovative bio-pharmaceutical company specializing in medical devices and compounds, which control bleeding and accelerate the natural healing process efficiently. Headquartered in Dublin, Ireland and with an R&D subsidiary in the Czech Republic, Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001. m-doc(TM) (Micro Dispersed Oxidized Cellulose; (http://www.m-doc.com )) is the end product of Alltracel's patented process, applied to cotton in the form of raw cellulose and is proven as an effective and efficient haemostatic (blood-stopping) agent in wound care devices. The route-to-market is via licensed trademark and ingredient supply agreements with existing recognized wound care brands. SEAL-ON(TM) (http://www.seal-on.com ) is the world's first first-aid treatment brand featuring stops bleeding m-doc(TM) as standard. The SEAL- ON(TM) range features seven different product delivery systems -- sprays, nasal plugs, patches, powder, plasters, dressings and blotters(TM) -- each designed for specific usage occasions and all containing the stops-bleeding m-doc(TM) ingredient brand. R&D on the core -- polysaccharides manipulation -- technology platform has confirmed significant and exciting potential applications beyond the Wound- care market, primarily in the Dermatological and Nutritional Foods market sectors. blotters(TM), m-doc(TM), SEAL-ON(TM) are all trademarks of Alltracel Pharmaceuticals Plc.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory